Global Pulmonary Arterial Hypertension Market is valued at USD 7.89 Billion in 2021 and is expected to reach USD 12.28 Billion by 2028 with a CAGR of 6.5% over the forecast period.
Scope of Global Pulmonary Arterial Hypertension Market Report: –
Pulmonary arterial hypertension (PAH) is a rare disease that affects the pulmonary arteries. It is characterized by narrow and blocked arteries and capillaries. Having pulmonary arterial hypertension (PAH) implies that have hypertension in the arteries that go from your heart to lungs. It’s not the same as having normal high blood pressure. With pulmonary arterial hypertension, the minuscule arteries in lungs become thin or blocked. It’s harder for blood to flow throughout them, and that brings the pulse up in your lungs. Heart needs to work harder to pump blood through those arteries, and inevitably the heart muscle gets weak. Under adverse conditions, it can also compromise the heart’s ability to pump blood, leading to eventual heart failure. PAH is characterized by shortness of breath, fatigue, and swelling of the ankles and feet. It is diagnosed by various tests such as an echocardiogram, computer tomography (CT) scan, chest X-ray, and ventilation-perfusion scan.
Request Free Sample PDF @ https://brandessenceresearch.com/requestSample/PostId/572
Some of the key players/Manufacturers involved in the Pulmonary Arterial Hypertension Market are:
- United Therapeutics Corporation
- Lupin Pharmaceuticals, Inc.
- Gilead Sciences, Inc.
- Bayer
- Johnson & Johnson
- GlaxoSmithKline
- Sandoz Inc. (Novartis)
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries, Inc.
- others
Global Pulmonary Arterial Hypertension Market Segmentation Analysis:
By Drug Class:
- Endothelin Receptor Antagonists (ERAs)
- SGC Stimulators
- PDE-5 Inhibitors
By Type:
- Generics
- Branded
By Route of Administration:
- Oral
- Inhalational
- Intravenous/ subcutaneous
Recent Developments
News- Bayer Launched KSA’s First Digital Platform for Pulmonary Hypertension Management
On February 23rd, 2022; Bayer launched Saudi Arabia’s first “digital hub” to improve the management of pulmonary hypertension (PH). The AAN Digital Hub designed to bridge the gap between the diagnosis and treatment of the condition during covid-19 epidemic focuses on facilitating virtual referrals for patients, as well as enabling the exchange of knowledge between primary care physicians and specialists and their patients.
Aerovate Launched a Clinical Trial of AV-101 in Pulmonary Arterial Hypertension
On December 17th, 2021; Aerovate Therapeutics started a Phase 2b/3 clinical preliminary that will test AV-101, the organizations exploratory breathed formulation of imatinib, in individuals with pulmonary arterial hypertension (PAH). The primary objective of the Phase 2b piece is to decide the impact on pulmonary arterial hypertension (PVR) — protection from blood stream in the lungs’ veins — following 24 weeks, or around a half year. Security, decency, and other clinical measures additionally will be surveyed. The test, called IMPAHCT (NCT05036135), is presently enrolling participants at the University of Kansas Medical Center in Kansas City, Kansas, with additional sites planned to open later.
Buy Now @ https://brandessenceresearch.com/Checkout?report_id=572
On Special Requirement Pulmonary Arterial Hypertension Market Report is also available for below region:
North America is Expected to Dominate the Global Pulmonary Arterial Hypertension Market
Geographically, North America is expected to dominate the global pulmonary arterial hypertension market within the forecast period due to the increasing prevalence of pulmonary arterial hypertension, rising cases of cardiovascular diseases, and presence of key players this region. The increasing prevalence of pulmonary arterial hypertension is increasing in the country attributed to the risk factors comprising smoking, HIV, alcohol consumption, and a sedentary lifestyle, among others. For instance; according to American Lung Association, on October 23rd, 2020; about 500-1000 new cases are diagnosed each year in the U.S. About 15-20% of patients with pulmonary arterial hypertension have inherited the condition. The increasing prevalence of cardiovascular diseases combined with the rising number of regulatory approvals being granted to new treatment medications are also fostering the market growth in this region. For instance; according to Cleveland Clinic, on May 5th, 2022; about 18 million people died of cardiovascular diseases in the US. Cardiovascular diseases are more likely to suffer from pulmonary arterial hypertension which is likely to boost the market growth.
North America
- S., Canada
Europe
- Germany, France, U.K., Italy, Spain, Sweden, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe
Asia-Pacific
- South_Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC
Latin America
- Mexico, Colombia, Brazil, Argentina, Peru, Rest of Latin America
Middle East and Africa
- Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA
Key Questions This Study Will Answer:
- What is the scope of growth in the Pulmonary Arterial Hypertension market?
- What is the core strategy for growth in the Pulmonary Arterial Hypertension market?
- What is the promise of growth in the long run?
- What is the promise of growth during the forecast period?
- How big is the Pulmonary Arterial Hypertension market?
- What are the main opportunities for growth in the Pulmonary Arterial Hypertension market?
- What are the key regions for future investments?
- What is the scope of growth in a particular country/ region of my interest?
- What are the risks involved in investing in the Pulmonary Arterial Hypertension market?
- Who are the key players in the Pulmonary Arterial Hypertension market?
- What are the core strategies of key players in the Pulmonary Arterial Hypertension market?
Browse Full and Sample Report Description Along with TOC & List of Facts & Figures Here
Other Trending Reports:
- Acetic Anhydride Market is valued at USD 6.65 Billion in 2021 and expected to reach USD 10.24 Billion by 2028 with a CAGR of 6.37% over the forecast period.
- Global Ethyl Acetate Market is valued at USD 5.16 Billion in 2021 and expected to reach USD 9.42 Billion by 2028 with a CAGR of 9.0% over the forecast period.
- vocal biomarkers market in terms of revenue was worth of USD 1901.1 Million in 2021 and is expected to reach USD 5131.8 Million in 2028, growing at a CAGR of 15.45% from 2021 to 2028.
- Clinical Microbiology Market
- Self-Testing Market
- Pulmonary Function Testing Systems Market Size, Share, And Trends Analysis 2022 to 2028
- North America Self Testing Market Size Share Companies & Trends Analysis Report & Forecasts 2022 – 2028
- Molecular Diagnostics Market
- Pharmaceutical Robots Market
- Healthcare consulting Market
I-Factor: Live Market intelligence platform
I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, changing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic. Register for free trial here at https://brandessenceresearch.com/i-factor/login/userRegister
Brandessence Market Research & Consulting Pvt ltd.
Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Follow Us: LinkedIn
Contact:
Email: vishal@brandessenceresearch.com
Email: Sales@brandessenceresearch.com
Corporate Sales: +44-2038074155
Asia Office: +917447409162